Infections in liver transplant recipients;Infecciones en los pacientes trasplantados de hígado

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 6, 2007, Pages 401-410

  Aguado, José María ^a   García Reyne, Ana ^a   Lumbreras, Carlos ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cytomegalovirus; Deep fungal infection; Liver transplant

Indexed keywords

BACTERIAL VIRULENCE; COURSE EVALUATION; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; GRAFT INFECTION; GRAFT RECIPIENT; HUMAN; HUMAN HERPESVIRUS 6; INFECTION PREVENTION; INFECTION RATE; LIVER GRAFT; LIVER TRANSPLANTATION; LUNG TUBERCULOSIS; MORTALITY; POLYMERASE CHAIN REACTION; REVIEW;

EID: 34547628181     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/s0213-005x(07)74314-8     Document Type: Review

References (65)

1. Blair JE, Kusne S. Bacterial, mycobacterial, and protozoal infections after liver transplantation - part I. Liver Transpl. 2005;11:1452-9.
2. George DL, Arnow PM, Fox AS, Baker AL, Thistlethwaite JR, Emond JC, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991;13:387-96.
3. Itoh K, Hashimoto T, Shimizu Y, Otobe Y, Tanaka M, Nakamura Y, et al. Bacterial and fungal infections after living related donor liver transplantation. Transplant Proc. 1996;28:2404-5.
4. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transpl. 2000;6:54-61.
5. Hollenbeak CS, Alfrey EJ, Souba WW. The effect of surgical site infections on outcomes and resource utilization after liver transplantation. Surgery. 2001;130:388-95.
6. Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75:79-83.
7. Durán FG, Piqueras B, Romero M, Carneros JA, De Diego A, Salcedo M, et al. Pulmonary complications following orthotopic liver transplant. Transpl Int. 1998;11 Suppl 1:255-9.
8. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30:322-7.
9. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation. 2003;75:194-8.
10. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42:195-203.
11. Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation. 2002;74:1381-6.
12. Kusne S, Blair JE. Viral and fungal infections after liver transplantation - part II. Liver Transpl. 2006;12:2-11.
13. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis. 1997;176:1135-40.
14. Teixeira R, Pastacaldi S, Davies S, Dhillon AP, Emery VC, Rolles K, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation. 2000;70:1454-8.
15. Gaeta A, Nazzari C, Angeletti S, Lazzarini M, Mazzei E, Mancini C. Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol. 1997;53:189-95.
16. Moreno MA. Viral infections in solid organ transplant recipients. Enferm Infecc Microbiol Clin. 1997;15 Suppl 2:22-33.
17. Keating MR. Antiviral agents. Mayo Clin Proc. 1992;67:160-78.
18. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866-72.
19. Morales JM, Muñoz MA, Fernández Zatarain G, García Cantón C, García Rubiales MA, Andrés A, et al. Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients. Nephrol Dial Transplant. 1995;10:882-3.
20. De Otero J, Gavalda J, Murio E, Vargas V, Calico I, Llopart L, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis. 1998;26:865-70.
21. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991;324:1057-9.
22. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 1997;350:1729-33.
23. Paya C, Humar A, Domínguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-20.
24. Díaz-Pedroche C, Lumbreras C, Del Valle P, San Juan R, Hernando S, Folgueira D, et al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant Proc. 2005;37:3766-7.
25. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl. 2006;12:112-6.
26. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005;79:85-90.
27. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis. 2001;3 Suppl 2:6-13.
28. Snydman DR, Falagas ME, Avery R, Perlino C, Ruthazer R, Freeman R, et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc. 2001;33:2571-5.
29. Pinna AD, Rakela J, Demetris AJ, Fung JJ. Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci. 2002;47:750-4.
30. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-51.
31. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 1996;29:141-51.
32. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis. 2002;186 Suppl 1:40-6.
33. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236:429-36; discussion 36-7.
34. Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002;74:1095-102.
35. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583-7.
36. Verschuuren EA, Stevens SJ, Van Imhoff GW, Middeldorp JM, De Boer C, Koeter G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100-4.
37. Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl. 2002;8:651-8.
38. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant. 2002;2:461-6.
39. Kadry Z, Bronsther O, Fung JJ. Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation. 1998;65:1140.
40. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis. 2006;26:273-84.
41. Fortún J, Martín-Dávila P, Álvarez ME, Sánchez-Sousa A, Quereda C, Navas E, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation. 2001;71:145-9.
42. Fortún J, Martín-Dávila P, Moreno S, De Vicente E, Nuño J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065-70.
43. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-96.
44. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.
45. Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother. 2003;37:90-8.
46. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. 2002;74:688-95.
47. Fortún J, Martín-Dávila P, Moreno S, Bárcena R, De Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003;52:813-9.
48. Shah T, Lai WK, Gow P, Leeming J, Mutimer D. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis. 2005;7:126-32.
49. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278-86.
50. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266-77.
51. Hernández-Pérez J, Yebra-Bango M, Jiménez- Martínez E, Sanz-Moreno C, Cuervas-Mons V, Alonso Pulpon L, et al. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin Infect Dis. 1999;29:918-21.
52. Chiche L, Lesage A, Duhamel C, Salame E, Malet M, Samba D, et al. Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation. 2003;75:166-8.
53. Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S, et al. Fungal infections in liver transplant recipients. Transplantation. 1985;40:347-53.
54. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore). 1988:67:132-43.
55. Wade JJ, Rolando N, Hayllar K, Philipott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation. An analysis of 284 patients. Hepatology. 1995;21:1328-36.
56. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 1995;14:375-82.
57. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996;62:926-34.
58. Miguélez M, Lumbreras C, Herrero JA, Aguado JM, Del Palacio A, Colina F, et al. Infección fúngica profunda en receptores de un trasplante de hígado: análisis de 21 casos. Med Clin (Barc). 1998;110:406-10.
59. Singh N, Wagener MM, Marino IR, Gayowski T. Trands in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation. 2002;73:63-7.
60. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure with low-dose amphotericin B. Clin Infect Dis. 1993;17:906-8.
61. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation. 1995;59:45-50.
62. Lumbreras C, Cuervas-Mons V, Jara P, Del Palacio A, Turrión VS, Barrios C, et al. Randomized trail of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis. 1996;174:583-8.
63. Winston DJ, Pakrasi A, busuttil RW. Prophylactic fluconazole in liver trasplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:729-37.
64. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. 2002;74:688-95.
65. Fortún J, López-San Román A, Velasco JJ, Sánchez-Sousa A, De Vicente E, Nuño J, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive cadidiasis. Eur J Clin Microbiol Infect Dis. 1997;16:314-8.